MAZE
Maze Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$29.70
+7.88%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.76
- Revenue estimate
- $333.3K
Latest reported
- Last report date
- Aug 12, 2026
- EPS actual
- -$0.76
- EPS estimate
- -$0.72
- Revenue actual
- —
- Revenue estimate
- $2.9M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +2.8%
- Revenue beats (12Q)
- 1
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $66
- PT range
- $46 – $110
- Analysts
- 5
5 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 12, 2026 | -$0.72 | -$0.76 | Miss -5.95% | — |
| May 12, 2026 | -$0.43 | -$0.45 | Miss -4.65% | $20.0M |
| Mar 25, 2026 | -$0.73 | -$0.65 | Beat 10.96% | — |
| Nov 6, 2025 | -$0.74 | -$0.66 | Beat 10.81% | — |
| Mar 31, 2025 | $0.45 | -$18 | Miss -4171.11% | — |
| Sep 30, 2024 | — | -$0.57 | — | $2.5M |
| Jun 30, 2024 | — | $3.18 | — | $165.0M |
| Mar 31, 2024 | — | -$0.74 | — | — |
| Dec 31, 2023 | — | -$0.61 | — | — |
| Sep 30, 2023 | — | -$0.57 | — | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026